PIK3CA and squamous cell carcinoma: However, PIK3CA and amplifications and mutations are also frequently detected in NSCLC, in 3.7–19% of cases, with 2.9–6.2% in adenocarcinoma and 8.9–33% in squamous cell carcinoma [265, 266].